Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure

References

• Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988–1994. J Allergy Clin Immunol. 2010;126(4):778–783. doi:10.1016/j.jaci.2010.06.050
   PubMed Web of Science ®Google Scholar
• Leonardi A, Piliego F, Castegnaro A, et al. Allergic conjunctivitis: a cross-sectional study. Clin Exp Allergy. 2015;45(6):1118–1125. doi:10.1111/cea.12536
   PubMed Web of Science ®Google Scholar
• Palmares J, Delgado L, Cidade M, Quadrado MJ, Filipe HP; Season Study Group. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol. 2010;20(2):257–264. doi:10.1177/112067211002000201
   PubMed Web of Science ®Google Scholar
• Mandell KJ, Clark D, Chu DS, Foster CS, Sheppard J, Brady TC. Randomized phase 2 trial of reproxalap, a novel reactive aldehyde species inhibitor, in patients with noninfectious anterior uveitis: model for corticosteroid replacement. J Ocul Pharmacol Ther. 2020;36(10):732–739. doi:10.1089/jop.2020.0056
   PubMed Web of Science ®Google Scholar
• Clark D, Sheppard J, Brady TC. A randomized double-masked phase 2a trial to evaluate activity and safety of topical ocular reproxalap, a novel RASP inhibitor, in dry eye disease. J Ocul Pharmacol Ther. 2021;37(4):193–199. doi:10.1089/jop.2020.0087
   PubMed Web of Science ®Google Scholar
• Clark D, Tauber J, Sheppard J, Brady TC. Early onset and broad activity of reproxalap in a randomized, double-masked, vehicle-controlled phase 2b trial in dry eye disease. Am J Ophthalmol. 2021;226:22–31. doi:10.1016/j.ajo.2021.01.011
   PubMed Web of Science ®Google Scholar
• Clark D, Cavanagh C, Shields A, Karpecki P, Sheppard J, Brady TC. Clinically relevant activity of the novel RASP inhibitor reproxalap in allergic conjunctivitis: the Phase 3 ALLEVIATE trial. Am J Ophthalmol. 2021;230:60–67. doi:10.1016/j.ajo.2021.04.023
   PubMed Web of Science ®Google Scholar
• Higdon A, Diers AR, Oh JY, Landar A, Darley-Usmar VM. Cell signalling by reactive lipid species: new concepts and molecular mechanisms. Biochem J. 2012;442(3):453–464. doi:10.1042/BJ20111752
   PubMed Web of Science ®Google Scholar
• Kalariya NM, Ramana KV, Srivastava SK, van Kuijk FJGM. Carotenoid derived aldehydes-induced oxidative stress causes apoptotic cell death in human retinal pigment epithelial cells. Exp Eye Res. 2008;86(1):70–80. doi:10.1016/j.exer.2007.09.010
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Niskanen H, Suuronen T, Kinnunen K, Salminen A, Kaarniranta K. Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells–implications for age-related macular degeneration (AMD). Immunol Lett. 2012;147(1–2):29–33. doi:10.1016/j.imlet.2012.05.005
   PubMed Web of Science ®Google Scholar
• Ackerman S, Smith LM, Gomes PJ. Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management. Ther Adv Chronic Dis. 2016;7(1):52–67. doi:10.1177/2040622315612745
   PubMed Web of Science ®Google Scholar
• Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge: a clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990;108(1):84–88. doi:10.1001/archopht.1990.01070030090035
   PubMed Web of Science ®Google Scholar
• Torkildsen G, Narvekar A, Bergmann M. Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model. Clin Ophthalmol. 2015;9:1703–1713. doi:10.2147/OPTH.S83263
   PubMedGoogle Scholar
• Abelson MB, Gomes PJ, Vogelson CT, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clin Ther. 2004;26(8):1237–1248. doi:10.1016/S0149-2918(04)80065-1
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Tubridy KL, Agahigian J, et al. A Phase 2 Exploratory Study of a novel interleukin-1 receptor inhibitor (EBI-005) in the treatment of moderate-to-severe allergic conjunctivitis. Eye Contact Lens. 2015;41(3):145–155. doi:10.1097/ICL.0000000000000152
   PubMed Web of Science ®Google Scholar
• Rønborg SM, Mosbech H, Johnsen CR, Poulsen LK. Exposure chamber for allergen challenge. The development and validation of a new concept. Allergy. 1996;51(2):82–88. doi:10.1111/j.1398-9995.1996.tb04562.x
   PubMed Web of Science ®Google Scholar
• Barchuk WT, Salapatek AM, Ge T, D’Angelo P, Liu X. A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol. 2013;132(4):838–846. doi:10.1016/j.jaci.2013.05.001
   PubMed Web of Science ®Google Scholar
• Patel P, Salapatek AM, Tantry SK. Effect of olopatadine-mometasone combination nasal spray on seasonal allergic rhinitis symptoms in an environmental exposure chamber study. Ann Allergy Asthma Immunol. 2019;122(2):160–166.e1. doi:10.1016/j.anai.2018.10.011
   PubMed Web of Science ®Google Scholar
• Schulze MM, Jones DA, Simpson TL. The development of validated bulbar redness grading scales. Optom Vis Sci. 2007;84(10):976–983. doi:10.1097/OPX.0b013e318157ac9e
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Ogundele A, et al. Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye. Clin Ophthalmol. 2019;13:2285–2292. doi:10.2147/OPTH.S226168
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease. Clin Ophthalmol. 2020;14:875–883. doi:10.2147/OPTH.S233194
   PubMed Web of Science ®Google Scholar
• White DE, Zhao Y, Jayapalan H, Machiraju P, Periyasamy R, Ogundele A. Physician satisfaction with anti-inflammatory topical medications for the treatment of dry eye disease. Clin Ophthalmol. 2020;14:931–938. doi:10.2147/OPTH.S237832
   PubMed Web of Science ®Google Scholar
• Hom MM, Nguyen AL, Bielory L. Allergic conjunctivitis and dry eye syndrome. Ann Allergy Asthma Immunol. 2012;108(3):163–166. doi:10.1016/j.anai.2012.01.006
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims; 2009. Available from: www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed September 28, 2021.
   Google Scholar
• European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of patient-reported outcome (PRO) measures in oncology studies; 2016. Available from: www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed September 28, 2021.
   Google Scholar
• Olsen MF, Bjerre E, Hansen MD, et al. Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med. 2017;15(1):35. doi:10.1186/s12916-016-0775-3
   PubMed Web of Science ®Google Scholar